Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Press Releases

865 Press Releases
DateTitleCompany
08 Jun 15 TECOS Merck’s Cardiovascular Safety Trial of JANUVIA (sitagliptin) Met Primary Endpoint in Patients with Type 2 Diabetes Merck,
Published by
Business Wire
08 Jun 15 Merck, Illumina and Genea Form the Global Fertility Alliance for Excellence in Assisted Reproductive Treatment Merck,
Published by
PharmiWeb.com
08 Jun 15 Merck's KEYTRUDA™ (pembrolizumab) receives conditional approval in Canada for the treatment of advanced melanoma Merck Canada Inc.,
Published by
PR Newswire
03 Jun 15 CORRECTING and REPLACING CAPTION Merck KGaA Darmstadt Germany Celebrates 125 Years in the U.S. with Launch of “Smarter Together” Initiative Merck KGaA,
Published by
Business Wire
03 Jun 15 Merck KGaA Darmstadt Germany Celebrates 125 Years in the U.S. with Launch of “Smarter Together” Initiative Merck KGaA,
Published by
Business Wire
01 Jun 15 FDA Accepts Supplemental Biologics License Application (sBLA) for KEYTRUDA® (pembrolizumab) Merck’s Anti-PD-1 Therapy in Advanced Non-Small Cell Lung Cancer and Grants Priority Review Merck,
Published by
Business Wire
01 Jun 15 Merck and Dynavax Announce New Collaboration Investigating the Combination of Immuno-Oncology Therapies Merck,
Published by
Business Wire
29 May 15 New Findings Show Durable Anti-Tumor Activity with KEYTRUDA® (pembrolizumab) Merck’s Anti-PD-1 Therapy in Patients with Advanced Head and Neck Cancer Regardless of PD-L1 Expression Status Merck,
Published by
Business Wire
28 May 15 Merck Submits U.S. New Drug Application for Grazoprevir/Elbasvir an Investigational Once-Daily Single Tablet Combination Therapy for Treatment of Chronic Hepatitis C Genotypes 1 4 and 6 Infection Merck,
Published by
Business Wire
28 May 15 Merck and NanoString Announce Clinical Research Collaboration to Develop an Immune-Related Gene Expression Assay for Use in the Development Program for KEYTRUDA® (pembrolizumab) Merck,
Published by
Business Wire
28 May 15 Merck Serono as Pioneer in Assisted Reproductive Treatments Takes Leading Role in Fertility Technologies Signing a Global Collaboration Agreement with Genea Biomedx Merck Serono,
Published by
PR Newswire
26 May 15 Merck Announces Third-Quarter 2015 Dividend Merck,
Published by
Business Wire
22 May 15 Merck Receives Positive CHMP Opinion for KEYTRUDA® (pembrolizumab) for the Treatment of Advanced Melanoma Merck,
Published by
Business Wire
21 May 15 Merck Millipore Enters Into Agreement to Acquire Exclusive Rights to Singulex's Ultra-Sensitive Single Molecule Counting (SMC™) Technology Merck Millipore,
Published by
PR Newswire
14 May 15 Merck KGaA Darmstadt Germany and Pfizer to Present Data at ASCO for Avelumab an Investigational Anti-PD-L1 Antibody Pfizer Inc. and Merck KGaA, Darmstadt, Germany,
Published by
Business Wire
28 Apr 15 Merck Announces the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) Met Primary Endpoint Merck,
Published by
Business Wire
28 Apr 15 Merck Announces Publication of Pivotal Data from Phase 3 Clinical Studies of ZERBAXA™ (Ceftolozane/Tazobactam) in The Lancet and Clinical Infectious Diseases Merck,
Published by
Business Wire
24 Apr 15 Merck’s Pivotal Phase 3 C-EDGE Program Evaluating Grazoprevir/Elbasvir Shows High Sustained Virologic Responses Across Broad Range of Patients with Chronic Hepatitis C Virus Infection Merck,
Published by
Business Wire
16 Apr 15 Alise Reicin Joins Merck Serono as Head of Global Clinical Development Merck Serono,
Published by
Business Wire
19 Apr 15 Early Findings with KEYTRUDA® (pembrolizumab) Merck’s Anti-PD-1 Therapy in Patients with Advanced Pleural Mesothelioma Presented at AACR Annual Meeting Merck,
Published by
Business Wire
20 Apr 15 TetraLogic and Merck to Collaborate on the Evaluation of Birinapant in Combination with KEYTRUDA® (pembrolizumab) in Solid Tumors Merck,
Published by
Business Wire
21 Apr 15 Merck Reaffirms Continued Commitment to Developing Innovative Medicines for the Treatment of Infectious Diseases at 25th Annual ECCMID Congress Merck,
Published by
Business Wire
24 Mar 15 Merck Announces New $10 Billion Share Repurchase Program Merck,
Published by
Business Wire
27 Mar 15 Merck to Hold First-Quarter 2015 Sales and Earnings Conference Call on April 28 Merck,
Published by
Business Wire
31 Mar 15 Syndax and Merck to Collaborate on Immuno-Oncology Study Evaluating Entinostat in Combination with KEYTRUDA® (pembrolizumab) in Lung Cancer and Melanoma Merck,
Published by
Business Wire
26 Mar 15 Merck Announces Collaboration with the American Diabetes Association to Educate Adults with Diabetes About Increased Risk for Serious Diseases like Pneumococcal Pneumonia Merck,
Published by
Business Wire
14 Apr 15 Phase III Trial of the Merck and NewLink Genetics Investigational Ebola Vaccine Initiated in Sierra Leone Merck,
Published by
Business Wire
23 Apr 15 Merck Announces Results from Phase 2/3 Study of Investigational Chronic Hepatitis C Therapy Grazoprevir/Elbasvir in Patients with Advanced Chronic Kidney Disease Merck,
Published by
Business Wire
23 Apr 15 Merck Millipore Introduces Magna ChIRP™ RNA Interactome Kits for the Analysis of Chromatin-Associated RNAs Merck Millipore,
Published by
PR Newswire
08 Apr 15 Grazoprevir/Elbasvir Merck’s Investigational Chronic Hepatitis C Therapy Granted FDA Breakthrough Therapy Designations; New Phase 2 and 3 Data in Multiple HCV Patient Types to be Presented at The International Liver CongressTM 2015 Merck,
Published by
Business Wire
Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.